| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3198 | 2019 |
| Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma A Engert, A Plütschow, HT Eich, A Lohri, B Dörken, P Borchmann, ... New England Journal of Medicine 363 (7), 640-652, 2010 | 1092 | 2010 |
| Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ... The Lancet 379 (9828), 1791-1799, 2012 | 744 | 2012 |
| Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ... J Clin Oncol 30 (6), 631-636, 2012 | 730 | 2012 |
| Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group … HT Eich, V Diehl, H Görgen, T Pabst, J Markova, J Debus, A Ho, B Dörken, ... J Clin Oncol 28 (27), 4199-4206, 2010 | 523 | 2010 |
| Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells EP von Strandmann, VR Simhadri, B von Tresckow, S Sasse, KS Reiners, ... Immunity 27 (6), 965-974, 2007 | 427 | 2007 |
| Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial B Von Tresckow, A Plütschow, M Fuchs, B Klimm, J Markova, A Lohri, ... J Clin Oncol 30 (9), 907-913, 2012 | 387 | 2012 |
| PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin … P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ... The Lancet 390 (10114), 2790-2802, 2017 | 363 | 2017 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 325 | 2022 |
| Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma SM Ansell, SM Horwitz, A Engert, KD Khan, T Lin, R Strair, T Keler, ... Journal of Clinical Oncology 25 (19), 2764-2769, 2007 | 324 | 2007 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 304 | 2021 |
| A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma A Rothe, S Sasse, MS Topp, DA Eichenauer, H Hummel, KS Reiners, ... Blood, The Journal of the American Society of Hematology 125 (26), 4024-4031, 2015 | 303 | 2015 |
| Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials K Behringer, H Mueller, H Goergen, I Thielen, AD Eibl, V Stumpf, ... Journal of clinical oncology 31 (2), 231-9, 2013 | 291 | 2013 |
| Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial T Elter, P Borchmann, H Schulz, M Reiser, S Trelle, R Schnell, M Jensen, ... Journal of Clinical Oncology 23 (28), 7024-7031, 2005 | 285 | 2005 |
| Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced … C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, ... Blood, The Journal of the American Society of Hematology 112 (10), 3989-3994, 2008 | 279 | 2008 |
| Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open … N Schmitz, M Nickelsen, M Ziepert, M Haenel, P Borchmann, C Schmidt, ... The lancet oncology 13 (12), 1250-1259, 2012 | 272 | 2012 |
| Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis N Skoetz, S Trelle, M Rancea, H Haverkamp, V Diehl, A Engert, ... The lancet oncology 14 (10), 943-952, 2013 | 249 | 2013 |
| Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) H Schulz, U Rehwald, F Morschhauser, T Elter, C Driessen, T Rüdiger, ... Blood, The Journal of the American Society of Hematology 111 (1), 109-111, 2008 | 245 | 2008 |
| Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in … P Borchmann, H Haverkamp, V Diehl, T Cerny, J Markova, AD Ho, ... Journal of Clinical Oncology 29 (32), 4234-4242, 2011 | 233 | 2011 |
| Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non … K Behringer, H Goergen, F Hitz, JM Zijlstra, R Greil, J Markova, S Sasse, ... The Lancet 385 (9976), 1418-1427, 2015 | 219 | 2015 |
